SEC Form SC 13D/A filed by IsoPlexis Corporation (Amendment)

$ISO
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
Get the next $ISO alert in real time by email
SC 13D/A 1 tm2318533d1_sc13da.htm SC 13D/A

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

IsoPlexis Corporation

(Name of Issuer)

 

Common stock, par value $0.001 per share

(Title of Class of Securities)

 

465005106

(CUSIP Number)

 

Paul Hodgdon

c/o Northpond Ventures, LLC

7500 Old Georgetown Road, Suite 800

Bethesda, MD 20814

240-800-1200

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

 

March 21, 2023

(Date of Event Which Requires Filing of this Statement)

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

CUSIP NO. 465005106 Page 2

 

1.

Names of Reporting Persons

 

Northpond Ventures, LP

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) ¨

3.

SEC Use Only

 

4.

Source of Funds (See Instructions)

 

OO

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

0

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

0

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

¨

13.

Percent of Class Represented by Amount in Row (11)

 

0.0%

14.

Type of Reporting Person (See Instructions)

 

PN

       

 

2 

 

 

CUSIP NO. 465005106 Page 3

 

1.

Names of Reporting Persons

 

Northpond Ventures GP, LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) ¨

3.

SEC Use Only

 

4.

Source of Funds (See Instructions)

 

OO

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

0

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

0

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

¨

13.

Percent of Class Represented by Amount in Row (11)

 

0.0%

14.

Type of Reporting Person (See Instructions)

 

OO

       

 

3 

 

 

CUSIP NO. 465005106 Page 4

 

1.

Names of Reporting Persons

 

Northpond Capital, LP

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) ¨

3.

SEC Use Only

 

4.

Source of Funds (See Instructions)

 

OO

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

0

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

0

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

¨

13.

Percent of Class Represented by Amount in Row (11)

 

0.0%

14.

Type of Reporting Person (See Instructions)

 

PN

       

 

4 

 

 

CUSIP NO. 465005106 Page 5

 

1.

Names of Reporting Persons

 

Northpond Capital GP, LLC

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) ¨

3.

SEC Use Only

 

4.

Source of Funds (See Instructions)

 

OO

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization

 

Delaware

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

0

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

0

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

¨

13.

Percent of Class Represented by Amount in Row (11)

 

0.0%

14.

Type of Reporting Person (See Instructions)

 

OO

       

 

5 

 

 

CUSIP NO. 465005106 Page 6

 

1.

Names of Reporting Persons

 

Michael P. Rubin

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

(a) ¨ (b) ¨

3.

SEC Use Only

 

4.

Source of Funds (See Instructions)

 

OO

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

 

¨

6.

Citizenship or Place of Organization

 

United States

Number of

Shares

Beneficially

Owned by

Each

Reporting

Person With

7.

Sole Voting Power

 

0

8.

Shared Voting Power

 

0

9.

Sole Dispositive Power

 

0

10.

Shared Dispositive Power

 

0

11.

Aggregate Amount Beneficially Owned by Each Reporting Person

 

0

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

 

¨

13.

Percent of Class Represented by Amount in Row (11)

 

0.0%

14.

Type of Reporting Person (See Instructions)

 

OO

       

 

6 

 

 

CUSIP NO. 465005106 Page 7

 

Item 1.Security and Issuer

 

This Amendment No. 2 to Schedule 13D amends and supplements statements on Schedule 13D filed on October 22, 2021, as amended on December 22, 2022 (the “Initial Statement”) with respect to the shares of Common Stock, $.0001 par value (the “Common Stock”) of IsoPlexis Corporation, a Delaware corporation (the “Issuer” or “IsoPlexis”) having its principal executive office at 35 NE Industrial Rd., Branford, CT 06405. Each Item below amends and supplements the information disclosed under the corresponding Item of the Initial Statement. Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment No. 2 shall have the same meaning herein as are ascribed to such terms in the Initial Statement. Except as set forth in this Amendment No. 2, the information contained in the Schedule 13D has not been updated or amended.

 

Item 2.Identity and Background

 

There are no amendments to Item 2 of the Initial Statement.

 

Item 3.Source and Amount of Funds or Other Consideration

 

There are no amendments to Item 3 of the Initial Statement.

 

Item 4.Purpose of Transaction

 

Item 4 of the Initial Statement is hereby amended and supplemented as follows:

 

On March 21, 2023, pursuant to the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Berkeley Lights. At the effective time of the Merger, each share of common stock, par value $0.001, of the Issuer was converted into the right to receive 0.6120 fully paid and nonassessable shares (the “Exchange Ratio”) of common stock, par value $0.00005, of Berkeley Lights, together with cash in lieu of fractional shares of Berkeley Lights Common Stock, if any.

 

Item 5.Interest in Securities of the Issuer

 

Item 5 of the Initial Statement is hereby amended and replaced in its entirety as follows:

 

The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3 and 6 is incorporated by reference in its entirety into this Item 5.

 

(a) and (b)

 

As of the date hereof, Northpond LP owns directly (and therefore is deemed the beneficial owner of) 0 shares of Common Stock, which represents approximately 0.0% of the number of shares of Common Stock outstanding. Northpond LP has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Common Stock held by it.

 

As the general partner of Northpond LP, Northpond GP may be deemed to be the indirect beneficial owner of the 0 shares of Common Stock beneficially owned by Northpond LP, which represents approximately 0.0% of the number of shares of Common Stock outstanding. Northpond GP has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Common Stock held by Northpond LP.

 

As of the date hereof, Northpond Capital owns directly (and therefore is deemed the beneficial owner of) 0 shares of Common Stock, which represents approximately 0.0% of the number of shares of Common Stock outstanding. Northpond Capital has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Common Stock held by it.

 

As the general partner of Northpond Capital, Northpond Capital GP may be deemed to be the indirect beneficial owner of the 0 shares of Common Stock beneficially owned by Northpond Capital LP, which represents approximately 0.0% of the number of shares of Common Stock outstanding. Northpond Capital GP has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Common Stock held by Northpond Capital LP.

 

7 

 

 

CUSIP NO. 465005106 Page 8

 

Mr. Rubin is the sole managing member of each of Northpond GP and Northpond Capital GP. As a result of the foregoing relationships, Mr. Rubin may be deemed to be the indirect beneficial owner of the 0 shares of Common Stock beneficially owned by Northpond LP and Northpond Capital LP, which represents approximately 0.0% of the number of shares of Common Stock outstanding. Mr. Rubin has the shared power to vote, or direct the voting of, and the shared power to dispose of, or direct the disposition of, the Common Stock held by Northpond LP and Northpond Capital LP.

 

Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

 

(c) None of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

 

(d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

 

(e) The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on March 21, 2023.

 

Item 6.Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

There are no amendments to Item 6 of the Initial Statement.

 

Item 7.Material to be Filed as Exhibits

 

There are no amendments to Item 7 of the Initial Statement.

 

8 

 

 

CUSIP NO. 465005106 Page 9

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: June 15, 2023 

     
 

Northpond Ventures, LP

 

By: Northpond Ventures GP, LLC, its general partner

     
  By: /s/ Patrick Smerkers
    Name: Patrick Smerkers
    Title: Chief Financial Officer, Partner
   
  Northpond Ventures GP, LLC
     
  By: /s/ Patrick Smerkers
    Name: Patrick Smerkers
    Title: Chief Financial Officer, Partner
   
 

Northpond Capital, LP

 

By: Northpond Capital GP, LLC, its general partner 

     
  By: /s/ Patrick Smerkers
    Name: Patrick Smerkers
    Title: Chief Financial Officer, Partner
   
  Northpond Capital GP, LLC
     
  By: /s/ Patrick Smerkers
    Name: Patrick Smerkers
    Title: Chief Financial Officer, Partner
     
  By /s/ Michael P. Rubin
    Name: Michael P. Rubin

 

9 

 

Get the next $ISO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ISO

DatePrice TargetRatingAnalyst
2/15/2022$17.00 → $12.00Overweight
Morgan Stanley
1/27/2022$20.00 → $15.00Outperform
SVB Leerink
11/19/2021$24.00Outperform
Evercore ISI Group
11/11/2021$17.00 → $20.00Outperform
SVB Leerink
11/2/2021$17.00Outperform
SVB Leerink
11/2/2021Outperform
Cowen & Co.
11/2/2021$16.00Overweight
Morgan Stanley
More analyst ratings

$ISO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

    PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IsoPlexis Reports Preliminary Full Year 2022 Revenue

    BRANFORD, Conn., Jan. 12, 2023 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ: ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced its preliminary unaudited revenue for the full year ended December 31, 2022. Total revenue for the full year ended December 31, 2022 is expected to be in the range of $16.6 to $16.8 million, representing a decrease of approximately 3% to 4% compared to $17.3 million for the full year ended December 31, 2021. Fourth quarter results were lower than expected primarily due to the timing of customer orders for instruments and lower consumable sales, as the previously described macroeconomic head

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

$ISO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ISO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ISO
Leadership Updates

Live Leadership Updates

See more
  • IsoPlexis Appoints Key Financial and Legal Hires from Leading Tools and Omics Companies

    BRANFORD, Conn., Nov. 30, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ: ISO), the leader in functional single-cell proteomics, today announced the appointment of Richard Rew as Senior VP, General Counsel and Secretary; Raj Khakhar as VP of Finance; and Manny Resendes as Global Controller. These three new appointments further strengthen Isoplexis' financial and legal teams. "We are excited to have Mr. Rew, Mr. Khakhar, and Mr. Resendes join our team at IsoPlexis," said Sean Mackay, CEO of IsoPlexis. "These recent hires will strengthen our ability to accelerate our growth trajectory a

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

    BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
  • IsoPlexis Bolsters Its Global Operational and Product Support Leadership

    BRANFORD, Conn., Nov. 12, 2021 /PRNewswire/ -- IsoPlexis (NASDAQ:ISO), the leader in functional single-cell proteomics, today announced the appointment of two new leadership positions at the company. Michelle Reid, Ph.D. joins IsoPlexis as VP of Service and Support, and Anthony Catalano joins as the Senior VP of Operations. With these appointments, IsoPlexis continues to strengthen its operations and product support teams, providing high need proteomic products with highly customer centric support. Ms. Reid comes to IsoPlexis with over 20 years of experience leading and devel

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$ISO
Financials

Live finance-specific insights

See more
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, CA and BRANFORD, Conn., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

    Complementary Technologies, Customer Bases, and Commercial Channels to Strengthen Leadership in High-Growth, Single-Cell Biology Significant Cost Synergies to Increase Profitability and Accelerate Breakeven Horizon in 2024, Earlier Than Berkeley Lights Expected as a Standalone Entity Companies to Host Joint Conference Call and Webcast Today at 5:00 p.m. ET EMERYVILLE, Calif. and BRANFORD, Conn., Dec. 21, 2022 /PRNewswire/ -- Berkeley Lights (NASDAQ:BLI), a life sciences tools company, and IsoPlexis (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced a definitive agreement under which Berkeley Lights will acquire IsoP

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IsoPlexis to Report Third Quarter 2022 Financial Results on November 10, 2022

    BRANFORD, Conn., Oct. 19, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health, today announced it will report financial results for the third quarter 2022 before market open on Thursday, November 10, 2022. Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.isoplexis.com. The webcast will be archived and available for replay after the event. About IsoPlexis IsoPlexis is empowering labs to leverage the ce

    $ISO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

$ISO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more